Previous close | 3.5800 |
Open | 3.5800 |
Bid | 2.5000 |
Ask | 3.4000 |
Strike | 8.00 |
Expiry date | 2025-01-17 |
Day's range | 3.5800 - 3.5800 |
Contract range | N/A |
Volume | |
Open interest | 10.07k |
RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU) after beginning treatment with ORLADEYO. The study was presented in a poster at the 2024 International Society for Pharmacoeconomics and O
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) defied analyst predictions to release its first-quarter results, which...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript May 6, 2024 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $-0.23. BCRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]